/pdf/inositol-trisphosphate-and-diacylglycerol-as-second-4drzjsg27y.pdf

Inositol trisphosphate and diacylglycerol as second messengers.

Phosphoinositides (PIs) make up only a small fraction of cellular phospholipids, yet they control almost all aspects of a cell's life and death. These lipids gained tremendous research interest as plasma membrane signaling molecules when discovered in the 1970s and 1980s. Research in the last 15 years has added a wide range of biological processes regulated by PIs, turning these lipids into one of the most universal signaling entities in eukaryotic cells. PIs control organelle biology by regulating vesicular trafficking, but they also modulate lipid distribution and metabolism via their close relationship with lipid transfer proteins. PIs regulate ion channels, pumps, and transporters and control both endocytic and exocytic processes. The nuclear phosphoinositides have grown from being an epiphenomenon to a research area of its own. As expected from such pleiotropic regulators, derangements of phosphoinositide metabolism are responsible for a number of human diseases ranging from rare genetic disorders to the most common ones such as cancer, obesity, and diabetes. Moreover, it is increasingly evident that a number of infectious agents hijack the PI regulatory systems of host cells for their intracellular movements, replication, and assembly. As a result, PI converting enzymes began to be noticed by pharmaceutical companies as potential therapeutic targets. This review is an attempt to give an overview of this enormous research field focusing on major developments in diverse areas of basic science linked to cellular physiology and disease.

Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation

Phencyclidine (PCP), a dissociative anesthetic and widely abused psychotomimetic drug, and MK-801, a potent PCP receptor ligand, have neuroprotective properties stemming from their ability to antagonize the excitotoxic actions of endogenous excitatory amino acids such as glutamate and aspartate. There is growing interest in the potential application of these compounds in the treatment of neurological disorders. However, there is an apparent neurotoxic effect of PCP and related agents (MK-801, tiletamine, and ketamine), which has heretofore been overlooked: these drugs induce acute pathomorphological changes in specific populations of brain neurons when administered subcutaneously to adult rats in relatively low doses. These findings raise new questions regarding the safety of these agents in the clinical management of neurodegenerative diseases and reinforce concerns about the potential risks associated with illicit use of PCP.

https://science.sciencemag.org/content/sci/244/4910/1360.full.pdf

Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs

https://www.cell.com/cell/pdf/0092-8674(89)90026-3.pdf

Neural and developmental actions of lithium: A unifying hypothesis

The pilocarpine model of temporal lobe epilepsy.

Administration of pilocarpine or physostigmine to rats treated with lithium chloride produced sustained limbic seizures, widespread brain damage, and increased concentrations of D-myo-inositol-1-phosphate (a metabolite of the phosphoinositides, lipids involved in membrane receptor function) in the brain. The syndrome was preventable with atropine. The physostigmine doses and concentrations of blood lithium that caused the syndrome are similar to those considered appropriate for psychiatric chemotherapy.

https://science.sciencemag.org/content/sci/220/4594/323.full.pdf

Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats.

The administration of LiCl (3.6 mequiv./kg/day) to adult male rats for 9 days results in an increase in the cerebral cortex level of myo-inositol-1-phosphate (M1P) to 4.43 +/- 0.52 mmol/kg (dry weight) compared with a control level of 0.24 +/- 0.02 mmol/kg. This establishes that the previously observed acute effect of lithium on M1P (Allison et al., 1976) is both prolonged and augmented by repeated doses of lithium. Larger doses of LiCl over a 3-5 day period result in even larger increases in M1P and a 35% decrease in myo-inositol. In each case, 90% of the increase is due to the D-enantiomer, evidence that lithium is largely producing this effect via phospholipase C-mediated phosphoinositide metabolism. Data are presented showing that lithium is an uncompetitive inhibitor of the hydrolysis of both D- and L-M1P by M1P'ase.

Evidence that Lithium Alters Phosphoinositide Metabolism: Chronic Administration Elevates Primarily d-myo-Inositol-1-Phosphate in Cerebral Cortex of the Rat

A single subcutaneous dose of 10 mEq/kg LiCl gives rise to an increase in the cerebral cortex level of myo-inositol-1-P (I1P) that closely follows cortical lithium levels and, at maximum, is 40-fold above the control value. Kidney and testis show smaller increases in I1P level following LiCl administration. The I1P level is still sixfold greater than that of untreated rat cortex 72 h later. In cortex, parallel increases also occur in myo-inositol-4-P (I4P) and myo-inositol 1,2-cyclic-P (cI1, 2P), whereas myo-inositol-5-P (I5P) remains unchanged. The cortical increases in I1P and I4P levels are partially reversed by administering 150 mg/kg of atropine 22 h after the LiCl, treatment that does not affect cI1, 2P. When doses of LiCl from 2 to 17 mEq/kg are given, the cerebral cortex levels of I1P and myo-inositol, measured 24 h later, are found to reach a plateau at about 9 mEq/kg of LiCl, whereas cortical lithium levels continued to increase with greater LiCl doses. Levels of ail three of the brain phosphoinositides are unchanged by the 10 mEq/kg LiCl dose, as is the uptake of 32Pi into these lipids. Chronic dietary administration of LiCl for 22 days showed that the effects of lithium on I1P and myo-inositol levels persist for that period. Over the course of the chronic administration of the lithium, levels of I1P, myo-inositol, and of lithium in cortex remained significantly correlated. We believe that these increases in inositol phosphates result from endogenous phosphoinositide metabolism in cerebral cortex and that lithium is capable of modulating that metabolism by reducing cellular myo-inositol levels. The size of the effect is a function of both lithium dose and the degree of stimulation of receptor-linked phosphoinositide metabolism. This property of lithium may explain part of its ability to moderate the symptoms of mania. Our chronic study suggests that prolonged administration of LiCl does not resuit in compensatory changes in myo-inositol-1-P synthase or myo-inositol-1-phosphatase.

Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis.

Rats were exposed to either 29 consecutive days of LiCl injections or 27 and 39 days of dietary Li2C03, followed by injected LiCl at the end of the diet to insure a constant level of exposure to the drug. At the end of the period of chronic exposure to lithium, the rats were sacrificed and brain myo-inositol-1-phosphate phosphohydrolase (myo-inositol monophosphatase) activity was measured. In none of the experiments was there any difference in the lithium-sensitive activity toward myo-inositol monophosphatase when comparing the control and chronic groups. These brains and those from another group of rats that had been given Li2C03 in their diet for 41 days, followed by 7 additional days of LiCl injections, were also examined for changes in the levels of the phosphoinositides. No reproducible differences in the absolute tissue levels of those lipids were found when control and chronic lithium groups were compared. These results are contrary to published reports which suggest that myo-inositol monophosphatase activity increases and that the phospha-tidylinositol level decreases in rat brain as a result of chronic administration of lithium.

Chronically administered lithium alters neither myo-inositol monophosphatase activity nor phosphoinositide levels in rat brain.

The metabolism of phosphoinositides that results from receptor-coupled processes in the CNS can be readily detected in rats treated with low doses of lithium chloride. Brain levels of myo-inositol 1-phosphate (IP) rise in response to agonists of this class of receptor and decrease on treatment with antagonists. For example, peripheral administration of the direct-acting muscarinic cholinergic agonist pilocarpine causes a rapid (<30 min) increase in the IP levels of cerebral cortex. Subsequent administration of the muscarinic antagonist atropine reverses the effect. The anticholinesterase physostigmine produces a similar IP elevation. Both of these agents produce seizures when given to lithium-treated rats. Because diazepam reduces the increase in IP while arresting seizures and because peripherally-administered kainic acid causes both seizures and an elevation in IP level that is partially reversed by atropine, we believe that the seizure activity itself contributes to the increase in IP observed. Nicotine, when administered subcutaneously to the lithium-treated rat, suppresses IP levels, while the two nicotinic cholinergic ganglionic blockers mecamylamine and pempidine give rise to atropine-reversible increases in IP that are comparable to the increases obtained with muscarinic agonists but without producing seizures. The effect of the nicotinic blockers is ascribed to disinhibition of Renshaw cell-like circuits.

Michael P. Honchar

Papers

Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats.

Evidence that Lithium Alters Phosphoinositide Metabolism: Chronic Administration Elevates Primarily d-myo-Inositol-1-Phosphate in Cerebral Cortex of the Rat

Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis.

Chronically administered lithium alters neither myo-inositol monophosphatase activity nor phosphoinositide levels in rat brain.

Detection of Receptor-Linked Phosphoinositide Metabolism in Brain of Lithium-Treated Rats